Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We have JP Morgan conference coming up, lots of PDUFA events, and some major data readouts. See below for a table full of major readouts you should keep an eye on. We're also running a holiday special of Amp Pro Annual at 60% Off ending soon. This includes all the BPIQ Pro features + monthly stock ideas and model portfolios. Learn more here.
Weekly Watchlist Highlights:
BIIB has a PDUFA date coming up 1/6/22 for Lecanemab for Alzheimer's disease. The BLA was accepted in July 2022. There was now Adcom meeting held prior to this date. This will be a big event for Alzheimer's companies.
SGENS's asset Tucatinib has a PDUFA target action date of January 19, 2023. Tucatinib could be approved for metastatic colorectal cancer and SGEN is in partnership with MRK for this asset. The NDA for Tucatinib was accepted in September 2022. Currently several other smid-cap biopharmas are in Phase 2 or 3 trials for mCRC as well.
The 41st Annual J.P. Morgan Health Care Conference is taking place in San Francisco, AC from January 9-12, 2023. Many of the smid-cap biopharma companies in the BPIQ.com database will be presenting at this conference, at which time companies may update timing of upcoming trials or readouts, or rarely, but sometimes give updated data at the conference. Plus, JPM week is a popular time for M&A or large commercial deals to be announced. We are very excited to see how JP Morgan kicks off 2023 M&A activity. See our recent November M&A post for Q4 activity.
Comments